AIMS: Pulmonary hypertension (PH) represents an important phenotype among the broader spectrum of patients with heart failure with preserved ejection fraction (HFpEF), but its mechanistic basis remains unclear. We hypothesized that activation of endothelin and adrenomedullin, two counterregulatory pathways important in the pathophysiology of PH, would be greater in HFpEF patients with worsening PH, and would correlate with the severity of haemodynamic derangements and limitations in aerobic capacity and cardiopulmonary reserve. METHODS AND RESULTS: Plasma levels of C-terminal pro-endothelin-1 (CT-proET-1) and mid-regional pro-adrenomedullin (MR-proADM), central haemodynamics, echocardiography, and oxygen consumption (VO2) were measured at rest and during exercise in subjects with invasively-verified HFpEF (n = 38) and controls free of HF (n = 20) as part of a prospective study. Plasma levels of CT-proET-1 and MR-proADM were highly correlated with one another (r = 0.89, P < 0.0001), and compared to controls, subjects with HFpEF displayed higher levels of each neurohormone at rest and during exercise. C-terminal pro-endothelin-1 and MR-proADM levels were strongly correlated with mean pulmonary artery (PA) pressure (r = 0.73 and 0.65, both P < 0.0001) and pulmonary capillary wedge pressure (r = 0.67 and r = 0.62, both P < 0.0001) and inversely correlated with PA compliance (r = -0.52 and -0.43, both P < 0.001). As compared to controls, subjects with HFpEF displayed right ventricular (RV) reserve limitation, evidenced by less increases in RV s' and e' tissue velocities, during exercise. Baseline CT-proET-1 and MR-proADM levels were correlated with worse RV diastolic reserve (ΔRV e', r = -0.59 and -0.67, both P < 0.001), reduced cardiac output responses to exercise (r = -0.59 and -0.61, both P < 0.0001), and more severely impaired peak VO2 (r = -0.60 and -0.67, both P < 0.0001). CONCLUSION: Subjects with HFpEF display activation of the endothelin and adrenomedullin neurohormonal pathways, the magnitude of which is associated with pulmonary haemodynamic derangements, limitations in RV functional reserve, reduced cardiac output, and more profoundly impaired exercise capacity in HFpEF. Further study is required to evaluate for causal relationships and determine if therapies targeting these counterregulatory pathways can improve outcomes in patients with the HFpEF-PH phenotype. CLINICAL TRIAL REGISTRATION: NCT01418248; https://clinicaltrials.gov/ct2/results? term=NCT01418248&Search=Search.

Brigham and Women's Hospital Harvard Medical School 75 Francis St Boston MA USA

Department of Cardiovascular Medicine Mayo Clinic and Foundation 200 1st Street SW Rochester MN USA

Institute for Clinical and Experimental Medicine IKEM Vídeňská 1958 9 Prague Czech Republic

Comment In

Eur Heart J. 2019 Dec 1;40(45):3718-3720. doi: 10.1093/eurheartj/ehz765. PubMed

See more in PubMed

Lam  CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM.  Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 2009;53:1119–1126. PubMed PMC

Hoeper  MM, Lam CSP, Vachiery JL, Bauersachs J, Gerges C, Lang IM, Bonderman D, Olsson KM, Gibbs JSR, Dorfmuller P, Guazzi M, Galie N, Manes A, Handoko ML, Vonk Noordegraaf A, Lankeit M, Konstantinides S, Wachter R, Opitz C, Rosenkranz S.  Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. Eur Heart J 2017;38:2869–2873. PubMed

Borlaug  BA, Obokata M.  Is it time to recognize a new phenotype? Heart failure with preserved ejection fraction with pulmonary vascular disease. Eur Heart J 2017;38:2874–2878. PubMed PMC

Gorter  TM, Obokata M, Reddy YNV, Melenovsky V, Borlaug BA.  Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. Eur Heart J 2018;39:2825–2835. PubMed PMC

Fayyaz  AU, Edwards WD, Maleszewski JJ, Konik EA, DuBrock HM, Borlaug BA, Frantz RP, Jenkins SM, Redfield MM.  Global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction. Circulation 2018;137:1796–1810. PubMed PMC

Vanderpool  RR, Saul M, Nouraie M, Gladwin MT, Simon MA.  Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol 2018;3:298.. PubMed PMC

Gorter  TM, van Veldhuisen DJ, Voors AA, Hummel YM, Lam CSP, Berger RMF, van Melle JP, Hoendermis ES.  Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. Eur Heart J Cardiovasc Imaging 2018;19:425–432. PubMed

Shah  SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ.  Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation 2016;134:73–90. PubMed PMC

Opitz  CF, Hoeper MM, Gibbs JSR, Kaemmerer H, Pepke-Zaba J, Coghlan JG, Scelsi L, D’Alto M, Olsson KM, Ulrich S, Scholtz W, Schulz U, Grünig E, Vizza CD, Staehler G, Bruch L, Huscher D, Pittrow D, Rosenkranz S.  Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 2016;68:368–378. PubMed

Assad  TR, Hemnes AR, Larkin EK, Glazer AM, Xu M, Wells QS, Farber-Eger EH, Sheng Q, Shyr Y, Harrell FE, Newman JH, Brittain EL.  Clinical and biological insights into combined post- and pre-capillary pulmonary hypertension. J Am Coll Cardiol 2016;68:2525–2536. PubMed PMC

Valero-Munoz  M, Li S, Wilson RM, Boldbaatar B, Iglarz M, Sam F.  Dual endothelin-A/endothelin-B receptor blockade and cardiac remodeling in heart failure with preserved ejection fraction. Circ Heart Fail 2016;9. pii: e003381. PubMed PMC

Nishikimi  T, Saito Y, Kitamura K, Ishimitsu T, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H.  Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 1995;26:1424–1431. PubMed

McMurray  JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ.  Plasma endothelin in chronic heart failure. Circulation 1992;85:1374–1379. PubMed

Moraes  DL, Colucci WS, Givertz MM.  Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000;102:1718–1723. PubMed

Jankowich  MD, Wu WC, Choudhary G.  Association of elevated plasma endothelin-1 levels with pulmonary hypertension, mortality, and heart failure in african american individuals: the Jackson Heart Study. JAMA Cardiol 2016;1:461–469. PubMed

Kakishita  M, Nishikimi T, Okano Y, Satoh T, Kyotani S, Nagaya N, Fukushima K, Nakanishi N, Takishita S, Miyata A, Kangawa K, Matsuo H, Kunieda T.  Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin Sci (Lond) 1999;96:33–39. PubMed

Cody  RJ, Haas GJ, Binkley PF, Capers Q, Kelley R.  Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504–509. PubMed

Nagaya  N, Kyotani S, Uematsu M, Ueno K, Oya H, Nakanishi N, Shirai M, Mori H, Miyatake K, Kangawa K.  Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004;109:351–356. PubMed

Matsui  H, Shimosawa T, Itakura K, Guanqun X, Ando K, Fujita T.  Adrenomedullin can protect against pulmonary vascular remodeling induced by hypoxia. Circulation 2004;109:2246–2251. PubMed

Heaton  J, Lin B, Chang JK, Steinberg S, Hyman A, Lippton H.  Pulmonary vasodilation to adrenomedullin: a novel peptide in humans. Am J Physiol 1995;268:H2211–H2215. PubMed

Wang  L, Zhou Y, Li M, Zhu Y.  Expression of hypoxia-inducible factor-1alpha, endothelin-1 and adrenomedullin in newborn rats with hypoxia-induced pulmonary hypertension. Exp Ther Med 2014;8:335–339. PubMed PMC

Obokata  M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA.  Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation 2017;135:825–838. PubMed PMC

Borlaug  BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM.  Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail 2010;3:588–595. PubMed PMC

Obokata  M, Reddy YN, Pislaru SV, Melenovsky V, Borlaug BA.  Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation 2017;136:6–19. PubMed PMC

Borlaug  BA, Kane GC, Melenovsky V, Olson TP.  Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J 2016;37:3293–3302. PubMed PMC

Kovacs  G, Olschewski A, Berghold A, Olschewski H.  Pulmonary vascular resistances during exercise in normal subjects: a systematic review. Eur Respir J 2012;39:319–328. PubMed

Jain  P, Rao S, Macdonald P, Kotlyar E, Jabbour A, Hayward C, Keogh A.  Diagnostic performance of pulmonary capacitance at rest and during exercise in idiopathic pulmonary arterial hypertension. Heart Lung Circ 2019;28:289–294. PubMed

Rudski  LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB.  Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685–713; quiz 786–8. PubMed

Shah  AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Liu L, Pitt B, Pfeffer MA, Solomon SD.  Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 2015;132:402–414. PubMed PMC

Obokata  M, Reddy YNV, Melenovsky V, Kane GC, Olson TP, Jarolim P, Borlaug BA.  Myocardial injury and cardiac reserve in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol 2018;72:29–40. PubMed PMC

Obokata  M, Olson TP, Reddy YN, Melenovsky V, Kane GC, Borlaug BA.  Hemodynamics, dyspnea, and pulmonary reserve in heart failure with preserved ejection fraction. Eur Heart J 2018;39:2810–2821. PubMed PMC

Reddy  YNV, Olson TP, Obokata M, Melenovsky V, Borlaug BA.  Hemodynamic correlates and diagnostic role of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. JACC Heart Fail 2018;6:665–675. PubMed PMC

Dorfs  S, Zeh W, Hochholzer W, Jander N, Kienzle RP, Pieske B, Neumann FJ.  Pulmonary capillary wedge pressure during exercise and long-term mortality in patients with suspected heart failure with preserved ejection fraction. Eur Heart J 2014;35:3103–3112. PubMed

Zile  MR, Bennett TD, El Hajj S, Kueffer FJ, Baicu CF, Abraham WT, Bourge RC, Warner Stevenson L.  Intracardiac pressures measured using an implantable hemodynamic monitor: relationship to mortality in patients with chronic heart failure. Circ Heart Fail 2017;10. pii: e003594. PubMed

Tromp  J, Khan MA, Klip IT, Meyer S, de Boer RA, Jaarsma T, Hillege H, van Veldhuisen DJ, van der Meer P, Voors AA.  Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc 2017;6. PubMed PMC

Giaid  A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732–1739. PubMed

Al-Naamani  N, Preston IR, Paulus JK, Hill NS, Roberts KE.  Pulmonary arterial capacitance is an important predictor of mortality in heart failure with a preserved ejection fraction. JACC Heart Fail 2015;3:467–474. PubMed PMC

van Duin  RWB, Stam K, Cai Z, Uitterdijk A, Garcia-Alvarez A, Ibanez B, Danser AHJ, Reiss IKM, Duncker DJ, Merkus D.  Transition from post-capillary pulmonary hypertension to combined pre- and post-capillary pulmonary hypertension in swine: a key role for endothelin. J Physiol 2019;597:1157–1173. PubMed PMC

Huang  W, Oliveira RKF, Lei H, Systrom DM, Waxman AB.  Pulmonary vascular resistance during exercise predicts long-term outcomes in heart failure with preserved ejection fraction. J Card Fail 2018;24:169–176. PubMed

Reddy  YNV, Obokata M, Koepp KE, Egbe AC, Wiley B, Borlaug BA.  The beta-adrenergic agonist albuterol improves pulmonary vascular reserve in heart failure with preserved ejection fraction. Circ Res 2019;124:306–314. PubMed PMC

Melenovsky  V, Hwang SJ, Lin G, Redfield MM, Borlaug BA.  Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014;35:3452–3462. PubMed PMC

Mohammed  SF, Hussain I, AbouEzzeddine OF, Abou Ezzeddine OF, Takahama H, Kwon SH, Forfia P, Roger VL, Redfield MM.  Right ventricular function in heart failure with preserved ejection fraction: a community-based study. Circulation 2014;130:2310–2320. PubMed PMC

Gorter  TM, Hoendermis ES, van Veldhuisen DJ, Voors AA, Lam CS, Geelhoed B, Willems TP, van Melle JP.  Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail 2016;18:1472–1487. PubMed

Obokata  M, Reddy YNV, Melenovsky V, Pislaru S, Borlaug BA.  Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 2019;40:689–697. PubMed PMC

Guazzi  M, Vicenzi M, Arena R, Guazzi MD.  Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011;124:164–174. PubMed

Bermejo  J, Yotti R, García-Orta R, Sánchez-Fernández PL, Castaño M, Segovia-Cubero J, Escribano-Subías P, San Román JA, Borrás X, Alonso-Gómez A, Botas J, Crespo-Leiro MG, Velasco S, Bayés-Genís A, López A, Muñoz-Aguilera R, de Teresa E, González-Juanatey JR, Evangelista A, Mombiela T, González-Mansilla A, Elízaga J, Martín-Moreiras J, González-Santos JM, Moreno-Escobar E, Fernández-Avilés F.  Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 2018;39:1255–1264. PubMed PMC

Luscher  TF, Enseleit F, Pacher R, Mitrovic V, Schulze MR, Willenbrock R, Dietz R, Rousson V, Hurlimann D, Philipp S, Notter T, Noll G, Ruschitzka F.  Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002;106:2666–2672. PubMed

Anand  I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Luscher TF.  Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:347–354. PubMed

Packer  M, McMurray JJV, Krum H, Kiowski W, Massie BM, Caspi A, Pratt CM, Petrie MC, DeMets D, Kobrin I, Roux S, Swedberg K; ENABLE Investigators and Committees. Long-term effect of endothelin receptor antagonism with Bosentan on the morbidity and mortality of patients with severe chronic heart failure: primary results of the ENABLE trials. JACC Heart Fail 2017;5:317–326. PubMed

Vachiery  JL, Delcroix M, Al-Hiti H, Efficace M, Hutyra M, Lack G, Papadakis K, Rubin LJ.  Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018;51. PubMed

Zile  MR, Bourge RC, Redfield MM, Zhou D, Baicu CF, Little WC.  Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. JACC Heart Fail 2014;2:123–130. PubMed

Nagaya  N, Satoh T, Nishikimi T, Uematsu M, Furuichi S, Sakamaki F, Oya H, Kyotani S, Nakanishi N, Goto Y, Masuda Y, Miyatake K, Kangawa K.  Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 2000;101:498–503. PubMed

Lisy  O, Jougasaki M, Schirger JA, Chen HH, Barclay PT, Burnett JC Jr. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol 1998;275:F410–4. PubMed

A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function

See more in PubMed

ClinicalTrials.gov
NCT01418248